Antimony in plasma and skin of patients with cutaneous leishmaniasis - Relationship with side effects after treatment with meglumine antimoniate

Tropical Medicine and International Health

Volumn 14, Issue 12, 2009, Pages 1515-1522

  Da Justa Neves, Diana Brito ^a   Caldas, Eloisa Dutra ^a   Sampaio, Raimunda Nonato Ribeiro ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Antimony; Cutaneous leishmaniasis; Inductively coupled plasma with mass spectrometry; Side effects

Indexed keywords

ANTIMONY; MEGLUMINE ANTIMONATE;

ANTIMONY; BLOOD; DISEASE TREATMENT; DOSE-RESPONSE RELATIONSHIP; HYPOTHESIS TESTING; INDUCTIVELY COUPLED PLASMA METHOD; LEISHMANIASIS; PLASMA; SYMPTOM;

ADULT; ADVERSE OUTCOME; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD EXAMINATION; BLOOD LEVEL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG INDUCED HEADACHE; EOSINOPHILIA; FEMALE; FEVER; HUMAN; INCIDENCE; LYMPHOCYTOSIS; MALE; MASS SPECTROMETRY; MYALGIA; NAUSEA; NEUTROPHILIA; PRURITUS; QT PROLONGATION; SIDE EFFECT; SKIN; SKIN LEISHMANIASIS; TISSUE LEVEL;

ADULT; ANTIMONY; ANTIPROTOZOAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MALE; MASS SPECTROMETRY; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; SKIN; TREATMENT OUTCOME;

EID: 70449338740     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02408.x     Document Type: Article

References (32)

1. Arana B, Rizzo N Diaz A (2001) Chemotherapy of cutaneous leishmaniasis: a review. Medical Microbiology and Immunology 190, 93 95.
2. Bazzi A, Nriagu JO, Inhorn MC Linder AM (2005) Determination of antimony in human blood with inductively coupled plasma - mass spectrometry. Journal of Environmental Monitoring 7, 1251 1254.
3. Croft SL Coombs GH (2003) Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology 19, 502 508.
4. Croft SL Yardley V (2002) Chemotherapy of leishmaniasis. Current Pharmaceutical Design 8, 319 342.
5. ® no tratamento da leishmaniose cutânea localizada. Revista da Sociedade Brasileira de Medicina Tropical 33, 535 543.
6. Dorea JG, Merchan-Hamann E, Ryan DE Holzbecher J (1990) Retention of antimony in skin biopsies of leishmaniasis patients after treatment with N-methylglucamine antimoniate. Clinical Chemistry 36, 680 682.
7. Faghihi G Tavakoli-Kia R (2003) Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clinical and Experimental Dermatology 28, 13 16.
8. Goullé JP, Mahieu L Castermant J et al. (2005) Metal and metalloid multi-elementary ICP-MS validation in whole blood, plasma, urine and hair reference values. Forensic Science International 153, 39 44.
9. Grevelink SA Lerner EA (1996) Leishmaniasis. Journal of the American Academy of Dermatology 34, 257 272.
10. Jaser MA, El-Yazigi A Croft SL (1995a) Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharmaceutical Research 12, 133 116.
11. Jaser MA, El-Yazigi A, Kojan M Croft SL (1995b) Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrobial Agents and Chemotherapy 39, 516 519.
12. Kashani MN, Firooz A, Eskandari SE et al. (2007) Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. European Journal of Dermatology 17, 513 515.
13. Lawn SD, Armstrong M, Chilton D Whitty CJM (2006) Electrocardiographic and biochemical adverse effects of sodium stibogluconate during reatment of cutaneous and mucosal leishmaniasis among returned travelers. Transactions of the Royal Society of Tropical Medicine and Hygiene 100, 264 269.
14. ® induces cell-mediated oxidative modifications of low density lipoprotein (LDL) Memórias do Instituto Oswaldo Cruz 91 (Suppl 272.
15. ® en intralésionnel dans le traitement de la leishmanisoe cutanée. Médecine et Maladies Infectieuses 36, 226 228.
16. Mattos MN, Friedman RK, Silva Filho IL Oliveira-Neto MP (2000) Pancreatite: um dos efeitos adversos da terapia antimonial na leishmaniose. Anais Brasileiros de Dermatologia 75, 45 50.
17. Miekeley N, Mortari S Schubach AO (2002) Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Analytical and Bioanalytical Chemistry 372, 495 502.
18. Mlika BR, El Aïdli S, Ben Brahim M et al. (2008) Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia. Médecine tropicale: revue du Corps de santé colonial 68, 499 501.
19. Mutjaba G Khalid M (1999) Weekly vs fortnightly intralesional meglumine antimoniate in cutaneous leishmaniasis. International Journal of Dermatology 38, 607 609.
20. Name RQ, Borges KT, Nogueira LSC, Sampaio JHD, Tauil P Sampaio RNR (2005) Clinical, epidemiological and therapeutic study of 402 patients with American cutaneous leishmaniasis attended at University Hospital of Brasilia, DF, Brazil. Anais Brasileiros de Dermatologia 80, 249 254.
21. Nogueira LSC Sampaio RR (2001) Estudo hospitalar da leishmaniose tegumentar americana (LTA): epidemiologia e tratamento. Anais Brasileiros de Dermatologia 76, 51 62.
22. Oliveira M, Amorim RFB, Freitas RA Costa ALL (2005) Óbito em caso de leishmaniose cutâneomucosa após o uso de antimonial pentavalente. Revista da Sociedade Brasileira de Medicina Tropical 38, 258 260.
23. Oliveira-Neto MP Mattos MS (2006) An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. Revista da Sociedade Brasileira de Medicina Tropical 39, 323 326.
24. Oliveira-Neto MP, Schubach A, Mattos M, Costa SCG Pirmez C (1997a) Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - an area of Leishmania (V) braziliensis transmission. International Journal of Dermatology 36, 463 468.
25. Oliveira-Neto MP, Schubach A, Mattos M, Costa SG Pirmez C (1997b) A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). American Journal of Tropical Medicine and Hygiene 57, 651 655.
26. Paula CDR, Sampaio JHD, Cardoso DR Sampaio RN (2003) Estudo comparativo da eficácia de isotionato de pentamidina administrada em três doses durante uma semana e de N-metil-glucamina 20 mg SbV/kg/dia durante 20 dias para o tratamento da forma cutânea da leishmaniose tegumentar americana. Revista da Sociedade Brasileira de Medicina Tropical 36, 365 371.
27. Rath S, Trivelin LA, Imbrunito TR et al. (2003) Antimoniais empregados no tratamento da leishmaniose: estado da arte. Química Nova 26, 550 555.
28. Rede intergerencial de Informações para a Saúde (RIPSA) (2008) http://wwwripsaorgbr/fichasIDB/levelphp?node=D&lang=pt, assessed on February 2008.
29. Reguera RM, Cubría JC Ordóñez D (1998) The pharmacology of leishmaniasis. General Pharmacology 30, 435 443. (Pubitemid 28102818)
30. ® e antimoniato de meglumina no tratamento da leishmaniose cutânea II Toxicidade bioquímica e cardíaca. Revista da Sociedade Brasileira de Medicina Tropical 33, 383 388.
31. Singh N (2006) Drug resistance mechanisms in clinical isolates of Leishmania donovani. The Indian Journal of Medical Research 123, 411 422.
32. World Health Organization (2008) Leishmaniasis: the disease and its epidemiology. http://wwwwhoint/leishmaniasis/en.